A tier · strong
BIG 1-98, MA.17 and the PPCOS II fertility trial give letrozole a broad randomised base across two distinct approved and guideline-endorsed uses, though all of it lies outside the ancillary context.
letrozole
Letrozole is the most potent of the third-generation non-steroidal aromatase inhibitors, approved for hormone receptor-positive breast cancer in postmenopausal women and widely used off-label but guideline-supported for ovulation induction in PCOS. Its randomised safety data consistently show bone loss, fractures, arthralgia and adverse lipid shifts as the price of near-complete estrogen suppression.
the explanation
Letrozole blocks estrogen production more completely than most similar drugs, which is why it works in breast cancer and also helps some women ovulate. The trade-off is measurable bone thinning, more fractures, joint pain and higher cholesterol.
regulatory status
Approved prescription medicine
FDA-approved in 1996 for adjuvant and extended adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer and for first- and second-line treatment of advanced disease. Use for ovulation induction is off-label in most jurisdictions but is guideline-endorsed as first line in PCOS. Not approved for use in men or as an estrogen-control adjunct.
how it works · proposed mechanism
Letrozole reversibly inhibits aromatase, cutting conversion of androgens to estrogens close to completion.
Near-complete aromatase blockade
Letrozole achieves 98.9% or greater whole-body aromatase inhibition at standard dosing, the highest of the third-generation agents. This produces 75-95% suppression of plasma estradiol, estrone and estrone sulfate.
Anti-tumour estrogen deprivation
In hormone receptor-positive breast cancer, removing the estrogenic growth signal slows or halts tumour proliferation. Randomised trials show this translates into improved disease-free survival versus tamoxifen.
Transient feedback release
In ovulation induction, short-course estrogen suppression removes negative feedback and raises pituitary FSH output. Because letrozole is cleared relatively fast and has no direct receptor antagonism, endometrium and cervical mucus are spared the persistent anti-estrogenic effects seen with clomifene.
what’s reported
evidence shape
32 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Letrozole's evidence is strong in two well-defined supervised settings: postmenopausal breast cancer, where a recurrence benefit justifies accepting bone and lipid toxicity, and short-course ovulation induction, where exposure lasts days per cycle. Neither supports ongoing off-label use as an estrogen-control adjunct alongside anabolic steroids, a context with no randomised data at all, no bone density monitoring, and where the drug's exceptional potency makes over-suppression of estradiol, itself a documented cause of bone loss, dyslipidaemia and sexual dysfunction in men, the most likely outcome rather than an edge case.
key published findings
- Regulatory data (Femara US label, adjuvant setting, 96-month follow-up versus tamoxifen): bone fractures 14.7% vs 11.4%, osteoporosis 5.1% vs 2.7%, arthralgia or arthritis 25.4% vs 20.6%, and hypercholesterolaemia 52.3% vs 28.6%.
- Regulatory data (Femara US label): letrozole suppresses plasma estradiol, estrone and estrone sulfate by 75% to 95% from baseline, with maximal suppression reached within two to three days and many values falling below assay detection limits.
- Human trial (PPCOS II, NEJM 2014, n=750 women with PCOS): letrozole achieved a live birth rate of 27.5% versus 19.1% for clomifene (rate ratio 1.44, P=0.0007), with significantly higher ovulation rates at each monthly visit from the second onward.
- Human trial (BIG 1-98, adjuvant letrozole vs tamoxifen in postmenopausal hormone receptor-positive early breast cancer): letrozole improved disease-free survival versus tamoxifen, with long-term follow-up published in Journal of Clinical Oncology in 2018 confirming the durability of the difference.
- Comparative pharmacology (published inhibition series): letrozole produces 98.9% or greater aromatase inhibition at standard dosing, exceeding anastrozole at 96.7-97.3%.
limitations of the evidence
- Oncology randomised data derive exclusively from postmenopausal women; there are no equivalent long-term outcome trials in men.
- Fertility use involves short cycles of exposure, so the fertility evidence base does not speak to chronic administration safety.
- Bone and lipid adverse effects were captured in monitored trial settings with intervention available, which is not comparable to unmonitored use.
documented safety signals
- Bone mineral density loss and osteoporosis: 5.1% versus 2.7% for tamoxifen at 96 months in the adjuvant setting.
- Increased bone fractures: 14.7% versus 11.4% for tamoxifen at 96 months.
- Arthralgia and arthritis in 25.4% versus 20.6% for tamoxifen, a common cause of treatment discontinuation.
- Marked adverse lipid effects, with hypercholesterolaemia reported in 52.3% versus 28.6% for tamoxifen.
- Hot flushes, night sweats, fatigue, mood disturbance and depression are common with profound estrogen deprivation.
- Vaginal dryness, dyspareunia and reduced libido.
- Hepatic enzyme elevation and rare hepatitis; rare angioedema and severe cutaneous reactions reported post-marketing.
- In fertility use: risk of multiple gestation and, less commonly, ovarian hyperstimulation, alongside hot flushes, fatigue and dizziness.
- Embryo-fetal toxicity; contraindicated in pregnancy and in women who may become pregnant outside supervised fertility protocols.
- In men, off-label use risks profound estradiol deficiency, which is independently associated with impaired bone mineralisation, adverse lipid profiles, reduced libido, and possible mood and cognitive effects, none characterised in randomised trials in this population.
identity
| full name | Letrozole |
| category | Ancillary & Endocrine |
| modality | small molecule |
| formula | C17H11N5 |
| molar mass | 285.31 g/mol |
| cas | 112809-51-5 |
| half-life | Approximately 2 days (terminal) |
laboratory handling
| storage | Tablets stored at controlled room temperature, approximately 25 degrees C, with excursions permitted to 15-30 degrees C, in the manufacturer's container. |
| solubility | White to yellowish crystalline powder, practically insoluble in water and freely soluble in dichloromethane and slightly soluble in ethanol. |
| co-studied with | Its exceptional aromatase potency, an advantage in oncology, makes it especially prone to excessive estradiol suppression when used off-label without monitoring; no randomised data exist for this application. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedFDA Drugs@FDA · 2014 · official
US prescribing information · 2024 · official
Selleck Chemicals product data · 2024 · official
New England Journal of Medicine · 2014 · randomized
Journal of Clinical Oncology · 2018 · randomized
others in Ancillary & Endocrine